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Progranulin (PGRN) is an autocrine growth factor with multiple functions. This review provides
updates about the interplays of PGRN with extracellular matrix proteins, proteolytic enzymes,
inﬂammatory cytokines, and cell surface receptors in cartilage and arthritis, with a special focus
on the interaction between PGRN and TNF receptors (TNFR) and its implications in inﬂammatory
arthritis. The paper also highlights Atsttrin, an engineered protein composed of three PGRN frag-
ments that prevents inﬂammation in several inﬂammatory arthritis models. Identiﬁcation of PGRN
as a ligand of TNFR and an antagonist of TNFa signaling, together with the discovery of Atsttrin, not
only betters our understanding of the pathogenesis of arthritis, but also provides new therapeutic
interventions for various TNFa-mediated pathologies and conditions, including rheumatoid
arthritis.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Progranulin (PGRN), also known as granulin epithelin precursor
(GEP), PC-cell-derived growth factor (PCDGF), proepithelin, and
acrogranin, is a 593-amino-acid autocrine growth factor. PGRN
contains seven-and-a-half repeats of a cysteine-rich motif (CX5–
6CX5CCX8CCX6CCXDX2HCCPX4CX5–6C) in the order P–G–F–B–A–
C–D–E, where A–G are full repeats and P is the half-motif [1]. PGRN
is abundantly expressed in rapidly cycling epithelial cells, in cells
of the immune system, in neurons [2], and in chondrocytes [3].
High levels of PGRN expression are also found in varieties of hu-
man cancers and contribute to tumorigenesis in breast cancer,
ovarian carcinoma, and multiple myeloma [2,4]. PGRN is known
to play a critical role in a variety of physiologic and disease pro-
cesses, including early embryogenesis [5], wound healing [6],
inﬂammation [7,8], and host defense [9]. PGRN also functions as
a neurotrophic factor [10,11] and mutations in the PGRN gene
resulting in partial loss of the PGRN protein cause frontotemporal
dementia [12–14]. PGRN was also isolated as an important regula-
tor of cartilage development and degradation [3,15–17]. For the
detailed introduction concerning the structure and function of
PGRN, please see the review paper written by Drs. Bateman and
Bennett [2]. In this paper, I will brieﬂy survey the association ofchemical Societies. Published by E
ew York University Medical
A. Fax: +1 212 598 6096.PGRN with its binding partners in arthritis, with a special focus
on the interaction between PGRN and TNFR as well as the discov-
ery of PGRN-derived Atsttrin that effectively prevents the onset
and progression of inﬂammatory arthritis [18–20].
2. PGRN associates with extracellular matrix proteins
The extracellular matrix of cartilage consists of several types of
collagens, proteoglycans, and other non-collagenous macromole-
cules, all of which interact to form a highly specialized connective
tissue [21]. Arthritis is a disease process characterized by the pro-
teolytic degradation of extracellular matrix components with sub-
sequent loss of articular cartilage and bone. Cartilage oligomeric
matrix protein (COMP), a prominent non-collagenous component
of cartilage, accounting for approximately 1% of the tissue’s wet
weight, has also been localized in tendon, bone (osteoblasts only),
and synovium [22–25]. COMP is a 524 kDa pentameric, disulﬁde-
bonded, multidomain glycoprotein composed of approximately
equal subunits (110 kDa each) [22,26]. Fragments of COMP have
been detected in diseased cartilage, synovial ﬂuid, and serum of
patients with knee injuries, posttraumatic, primary osteoarthritis
(OA), and rheumatoid arthritis (RA) [27–29]. Monitoring of COMP
levels in either joint ﬂuid or serum can be used to assess the pres-
ence and progression of arthritis [30–35]. Mutations in the human
COMP gene have been linked to the development of pseudoachon-
droplasia and multiple epiphyseal dysplasia, autosomal-dominant
forms of short-limb dwarﬁsm characterized by short stature,lsevier B.V. All rights reserved.
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42]. PGRNwas identiﬁed as a COMP-binding growth factor in an ef-
fort to deﬁne the biological functions of COMP [16]. PGRN directly
binds to COMP both in vitro and in vivo. PGRN selectively interacts
with the EGF repeat domain of COMP but not with the COMP’s
other three functional domains. The Granulin A repeat unit of
PGRN is required and sufﬁcient for association with COMP. Overex-
pression of PGRN stimulates the proliferation of chondrocytes and
this stimulation is enhanced by COMP. In addition, COMP appears
to be required for PGRN-mediated chondrocyte proliferation, since
chondrocyte proliferation induced by PGRN is dramatically inhib-
ited by an anti-COMP antibody.
Extracellular matrix protein 1 (ECM1), a COMP-associated ma-
trix protein [43], was also found to interact with PGRN. COMP
and ECM1, however, exert an opposite effect on PGRN cell surface
localization: COMP enhances, whereas ECM1 inhibits, cell surface
appearance of PGRN (Kong and Liu, unpublished data). Perlecan,
a heparan sulfate proteoglycan important for chondrocyte differ-
entiation and function [44,45], was known to bind to ECM1 [46].
Interestingly, PGRN was also reported to associate with perlecan,
and the PGRN–perlecan interaction was suggested to modulate tu-
mor growth [47]. Whether this interaction is also important for the
PGRN activity in cartilage and arthritis remains to be delineated.3. PGRN associates with proteolytic enzymes
During inﬂammation, neutrophils and macrophages release ser-
ine proteases that digest PGRN into individual 6 kDa granulin units,
which are actually pro-inﬂammatory and can neutralize the anti-
inﬂammatory effects of intact PGRN [7,8]. Both neutrophil elastase
(NE) and proteinase 3 (PR3) are known to digest PGRN at its linker
regions, resulting in the liberation of individual granulin units
[7,8], and are involved in the PGRN conversion during neutrophil
activation in vitro and immune complex-mediated inﬂammation
in vivo [7,48]. PGRN’s anti-inﬂammatory actions are protected by
its binding proteins, which include the secretory leukocyte prote-
ase inhibitor [8] and apolipoprotein A1 [49], both of which bind
to PGRN and protect it against proteolytic degradation.
In addition to serine proteases, several metalloproteinases from
both ADAMTS and MMP families were also found to associate with
and degrade PGRN [3,15,50–52]. PGRN binds directly to ADAMTS-7
and ADAMTS-12 in vitro and in chondrocytes, and the four C-ter-
minal TSP motifs of ADAMTS-7/-12 and each granulin unit of PGRN
mediate their interactions. Additionally, PGRN co-localizes with
ADAMTS-7 and ADAMTS-12 on the cell surface of chondrocytes
[15,50]. ADAMTS-7 acts as a new PGRN-convertase and neutralizes
PGRN-stimulated endochondral bone formation [50]. More signiﬁ-
cantly, PGRN inhibits COMP degradation by ADAMTS-7/-12
through the following two mechanisms: (a) competitive inhibition
through direct protein-protein interactions with ADAMTS-7/-12
and COMP; and (b) inhibition of TNFa-induced ADAMTS-7/-12
expression [15,17]. Furthermore, PGRN levels are signiﬁcantly ele-
vated in patients with either osteroarthritis or rheumatoid arthritis
[15]. These observations demonstrate a novel protein–protein
interaction network among PGRN growth factor, ADAMTS-7 and
ADAMTS-12 metalloproteinases, and COMP extracellular matrix
protein. Furthermore, PGRN functions as a speciﬁc inhibitor of
ADAMTS-7/-12-mediated COMP degradation and may play a sig-
niﬁcant role in preventing the destruction of joint cartilage in
arthritis.
In addition, PGRN was also isolated as a novel substrate of the
membrane type 1 matrix metalloproteinase (MMP-14) in a quanti-
tative proteomic evaluation of the inhibitor of MMP-14 with iso-
tope-coded afﬁnity tag labeling and tandem mass spectrometry
[52].4. PGRN associates with cell surface receptors
4.1. PGRN directly binds to TNFR and antagonizes TNFa actions
Although PGRN plays crucial roles in multiple physiological and
pathological conditions, efforts to exploit the actions of PGRN and
understand the mechanisms involved have been hampered by our
inability to identify its binding receptor(s) [2]. To address this issue,
we performed a global genetic screen that led to the identiﬁcation of
TNFR2 as the PGRN-associated receptor [18]. PGRN exhibited higher
afﬁnity for TNF receptors, especially TNFR2 when compared with
TNFa. In contrast to TNFa, which demonstrated higher afﬁnity for
TNFR1 than TNFR2, PGRN exhibited comparable binding afﬁnity
for TNFR1 and TNFR2 [18]. PGRN acts as a physiological antagonist
of TNFa signaling and disturbs the binding of TNFa and TNFR [18].
Previous reports have demonstrated that PGRN potently inhibits
TNF-mediated neutrophil activation [8] and cartilage degradation
[3]. In addition, the deletion of PGRN led to a signiﬁcant increase
inhydrogenperoxide inneutrophils andnitric oxide inbonemarrow
derived macrophages, and a marked increase in TNFa-induced
COMP degradation in cartilage explants [18].4.2. PGRN-deﬁcient mice are susceptible to collagen-induced arthritis,
and administration of PGRN abolishes the severe inﬂammatory
arthritis seen in collagen-challenged PGRN-deﬁcient mice
To examine the role of endogenous PGRN during inﬂammation
in vivo, we investigated the clinical and histopathological features
of PGRN/mice and their control littermates in a mouse model of
collagen-induced arthritis (CIA) [53,54]. PGRN/ mice immunized
with collagen II developed higher severity inﬂammatory arthritis
and increased bone and joint destruction as compared with their
control littermates. We also observed a signiﬁcant increase in the
arthritis severity score and a 100% incidence of arthritis in
PGRN/ mice, which was dramatically higher when compared
with the 40% arthritis incidence of wild-type control CIA C57B6
mice. Importantly, administration of recombinant PGRN com-
pletely blocked disease progression in PGRN-deﬁcient CIA mice.
Collectively, these data suggest that the loss of PGRN expression
in vivo results in hyper-susceptibility to collagen induced arthritis,
which can be entirely reversed by the administration of recombi-
nant PGRN [18].
4.3. Deletion of the PGRN gene exacerbates, whereas recombinant
PGRN prevents, the spontaneous development of inﬂammatory
arthritis in TNF transgenic mice
To determine whether the anti-inﬂammatory actions of PGRN
occur through the suppression of TNFa signaling in vivo, we de-
leted the PGRN gene in TNF transgenic mice (TNF-Tg). TNF-Tg mice
are known to develop an inﬂammatory arthritis phenotype sponta-
neously [55,56]. The deletion of PGRNmarkedly hastened the onset
of arthritis. 12-week-old TNF-Tg/PGRN/ and TNF-Tg/PGRN+/
mice developed severe swelling and joint deformation, which con-
tributed to a signiﬁcant loss of mobility. In contrast, TNF-Tg mice
developed only mild signs of inﬂammation. TNF-Tg/PGRN/ and
TNF-Tg/PGRN+/ mice demonstrated signiﬁcantly increased syno-
vitis, pannus formation, destruction of the ankle joints, and loss
of cartilage matrix. Treatment of TNF-Tg mice with recombinant
PGRN resulted in the elimination of any visual signs of arthritis
and a dramatically reduced arthritis severity score. Interestingly,
at seven days following the cessation of PGRN treatment, signs of
arthritis began to develop. Taken together, these data suggest that
PGRN may exert its anti-inﬂammatory effects through, at least in
part, the inhibition of TNF/TNFR signaling in vivo.
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Recently, Hu and colleagues identiﬁed sortilin as a neuronal
receptor for PGRN that facilitates its endocytosis and regulates
PGRN levels in vitro and in vivo [57], suggesting that sortilin-med-
iated PGRN endocytosis may play a role in the pathophysiology of
the neurodegenerative disease frontotemporal lobar degeneration
[57,58]. Sortilin, highly enriched in the vertebrate central nervous
system [59], is also known to interact with the neural growth fac-
tors, including nerve growth factor (NGF) [60] and brain-derived
neurotrophic factor (BDNF) [61]. In addition, sortilin also binds to
other polypeptides such as neurotensin, sphingolipid activator pro-
tein and lipoprotein lipase and has been suggested to be involved
in proper intracellular trafﬁcking of these polypeptides [62–66].
5. Discovery of PGRN-derived Atsttrin
Although PGRN has anti-inﬂammatory activity [7,8,18], it is un-
likely that PGRN can be directly employed for treating inﬂamma-
tory disorders due to its multiple functions, especially its
oncogenic activity [2]. Thus, we put a lot of effort into constructing
a molecule that remains TNFR binding but loses PGRN’s oncogenic
action. We started with the identiﬁcation of the domains of PGRN
required for its interaction with TNF receptors. A series of PGRN
mutants were constructed and analyzed for their interactions with
TNFR2. No single granulin unit (A–G) or linker region was able to
bind to TNFR2, suggesting that the binding domain of PGRN may
span granulin unit and linker. To examine this hypothesis, we ﬁrst
expressed each granulin with its immediately adjacent down-
stream linker and found that granulin F plus linker P3 exhibited
a weak interaction with TNFR2. Next, we linked each granulin to
its immediately adjacent upstream linker; P4-granulin A and P5-
granulin C both demonstrated weak binding afﬁnity to TNFR2. Fi-
nally, we linked all three fragments identiﬁed above to generate
an engineered mutant (referred to as FAC) [18]. These data are in
accordance with the ﬁndings that granulin F, A, and C are the gran-
ulin domains most capable of independent folding and that these
granulin domains have N and C terminal subdomains that are
structurally independent by NMR [67]. Interestingly, FAC exhibited
an even stronger binding afﬁnity to TNFR2 than PGRN [18]. To
identify the minimal engineered mutant protein with retained
binding afﬁnity, we generated the mutant 2/3 (FAC), which is iden-
tical to FAC except that only 2/3 of each granulin unit was included.
We observed that 2/3 (FAC) binds to TNFR2 with a lower afﬁnity
than FAC. A further reduction from 2/3 to 1/2 of each granulin unit
did not alter the binding afﬁnity; however, a reduction to 1/4 com-
pletely abolished the interaction with TNFR2. Taken together, these
results suggest that a mutant composed of half units of granulins A,
C, and F plus linkers P3–P5 appears to be the ‘‘minimal’’ engineered
molecule that retains afﬁnity to TNFR2. This molecule was referred
to as Atsttrin (Antagonist of TNF/TNFR Signaling via Targeting to
TNF Receptors) [18].
When compared with TNFa, recombinant Atsttrin exhibited
higher binding afﬁnity for TNFR2, but lower afﬁnity for TNFR1.
Similar to PGRN, Atsttrin inhibited the interaction between TNF
and TNFR, and in turn, the downstream events of TNF/TNFR signal-
ing, such as TNFa-induced proinﬂammatory cell activation, cyto-
toxicity, and osteoclastogenesis. In addition, Atsttrin exhibited
potent anti-inﬂammatory responses in vivo . Administration of
either PGRN or Atsttrin resulted in reduced disease severity in col-
lagen antibody induced arthritis (CAIA) model, and both agents sig-
niﬁcantly delayed the progression of arthritis. Furthermore,
Atsttrin was more effective than PGRN in delaying the onset of
inﬂammation. In the CIA model, DBA/1 mice treated with PGRN
or Atsttrin demonstrated markedly reduced pathology, withAtsttrin-treated mice bearing marked similarity to normal mice.
In addition, both PGRN- and Atsttrin-treated mice were found to
have decreased circulating levels of fragmentary COMP, a marker
for cartilage breakdown. We also conﬁrmed the therapeutic efﬁ-
cacy of Atsttrin in TNF transgenic mouse model. Consistent with
the results observed in the CAIA and CIA models, the administra-
tion of Atsttrin markedly suppressed arthritis progression, and
notably eliminated signs of inﬂammation. In addition, signs of
inﬂammation returned following the cessation of Atsttrin
treatment.
6. Comparison of Atsttrin with current TNF inhibitors
6.1. Unique mechanism of action
Since tissue destruction in RA is caused by inﬂammatory medi-
ators, the currently approved biological therapies for RA treatment
primarily target cytokines such as TNFa. Although treatment with
these agents is highly effective in ameliorating disease and improv-
ing quality of life in some patients with moderate-to-severe dis-
ease, current TNFa inhibitors fail to provide effective treatment
for up to 50% of RA patients [68]. Atsttrin demonstrates features
that suggest it may compare favorably to these established agents.
For example, all currently marketed anti-TNF therapies bind to the
TNFa ligand, while, in contrast, Atsttrin binds to TNFR and not to
TNFa itself. Due to this alternate mechanism of action, Atsttrin
may be effective for the patients who fail to respond to current
TNFa blockers [68]. The potential advantages of an ‘anti-TNFR’ ap-
proach (in contrast to an ‘anti-TNF’ approach) to the treatment of
human chronic inﬂammatory and autoimmune conditions have
been previously reviewed [69]. In addition, drugs such as Anakinra
and Actemra, which target the IL-1 receptor and IL-6 receptor, have
demonstrated that the selective targeting of cytokine receptors can
deliver a highly effective clinical outcome [70].
6.2. Activation of TNFR2 protective pathway
Growing evidences indicate that TNFR2 signaling has a protec-
tive role in inﬂammatory arthritis and joint erosion [71,72]. It ap-
pears that PGRN is the optimal ligand for TNFR2, in terms of both
biochemical (PGRN exhibits approximately 600-fold higher bind-
ing afﬁnity to TNFR2 than TNFa) and functional evidences (PGRN
and TNFR2 mediate beneﬁcial and protective roles in the inﬂam-
matory processes [7,8,71,72]). Treg cells that only express high lev-
els of TNFR2 but do not express TNFR1 [73–75] were known to play
a critical role in the prevention of autoimmunity and other patho-
logical immune responses [76,77]. PGRN signiﬁcantly protects Treg
from a negative regulation by TNFa in a dose-dependent manner
[18,75]. In addition, PGRN selectively promotes the differentiation
of Treg from Naïve T cells [18]. Furthermore, TNFR2/ CIA mice
are less sensitive to Atsttrin treatment although Atsttrin exhibits
therapeutic effects in either of TNFR-null CIA mice [18]. Collec-
tively, PGRN and probably its derived Atsttrin, exert their protec-
tive effects in the pathogenesis of mouse models of inﬂammatory
arthritis through multiple mechanisms: (1) acting as antagonists
of TNF-mediated inﬂammatory response; (2) regulating the func-
tions of Treg in a TNFR2-dependent manner; and (3) stimulating
Treg differentiation. Thus, PGRN is not only a novel antagonist of
TNFa, but an important mediator of the immune system as well.
6.3. Tumor suppression activity
Study indicates that administration of current TNF blockers,
such as Humira (adalimumab) and Remicade (inﬂiximab), in-
creases the cancer risk [78–81], but the underlying molecular
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growth factor [2,82–85] as a novel ligand of TNFR may help us to
understand this puzzling phenomenon. As illustrated in Fig. 1,
PGRN and TNF, two ligands of TNFR, reach balance under physio-
logical conditions. If the balance is disturbed, for instance higher
TNF activity, it will result in inﬂammation and autoimmune dis-
eases, including rheumatoid arthritis. In contrast, if PGRN activity
is too high, this may cause excessive cell growth and tumorgenesis
(Fig. 1A). Current TNF inhibitors all bind to TNF, and inhibit TNF-
mediated inﬂammation. Once the TNF ligand is blocked, more
TNFR will become available to a second ligand, i.e., PGRN. In other
words, the PGRN activity may be enhanced, which may result in in-
creased cancer incidence (Fig. 1B). Atsttrin, which directly binds to
TNFR rather than TNF ligand, does not increase cancer incidence. In
contrast it actually acts as a tumor suppressor and has potential for
treating cancers in which PGRN is highly active, such as liver and
breast cancers (Fig. 1C). Indeed, Atsttrin has been shown to inhibitFig. 1. Proposed model for comparing TNFa blockers and Atsttrin in mediating
inﬂammation and cancer. (A) PGRN and TNFa, two ligands of TNFR that links
inﬂammation and cancer, bind to TNFR. (B) Current TNFa inhibitors bind to TNFa
and inhibit TNF-mediated inﬂammation. (C) Atsttrin, which directly binds to TNFR
rather than TNFa, inhibits both inﬂammation and cancerogenesis.PGRN-stimulated cell proliferation of several cancer cell lines
tested (Tang and Liu, unpublished data).
6.4. Stability
The pharmacokinetic proﬁle assay of Atsttrin in mice indicated
that Atsttrin was well absorbed following intraperitoneal adminis-
tration and demonstrated high stability with a half-life of about
120 h [18]. In accordance with its long half-life, a single dose of
Atsttrin (10 mg/kg) could effectively delay the onset of inﬂamma-
tion for approximately three weeks [18]. PGRN-converting prote-
ases, such as elastase and proteinase-3, are known to digest
PGRN at its linker regions, resulting in the liberation of individual
granulin units [7,8]. Interestingly, the presence of intact granulin
units is required for PGRN to bind ADAMTS-7 and ADAMTS-12,
two metalloproteinases known to associate with and digest PGRN
[15,50]. Thus, the high stability of Atsttrin may be at least partially
explained by its lack of intact granulins, which allows it to escape
the proteolytic activity of degradative enzymes.6.5. Efﬁcacy
Atsttrin exhibits highly potent anti-inﬂammatory activity,
which surpasses PGRN itself, in vivo [18]. This occurred despite
the observation that PGRN binds to TNFR with a higher afﬁnity
than Atsttrin, a ﬁnding that may be explained by the fact that Atst-
trin contains only partial granulin units and would not be expected
to release any intact pro-inﬂammatory granulin units upon expo-
sure to PGRN-converting enzymes such as elastase [8], protein-
ase-3 [7], and ADAMTS-7 [50]. In addition, Atsttrin exhibited a
signiﬁcantly longer half-life (120 h) when compared to PGRN
(40 h). In addition, Atsttrin is also more efﬁcacious than the cur-
rent anti-TNFa therapy, including etanercept (Enbrel) and ada-
limumab (Humira), in several preclinical inﬂammatory arthritis
models tested (Tang, et al., unpublished data) [18]. Whether the
efﬁcacy of Atsttrin observed in animal models can be translated
into human patients remains to be determined.
6.6. Preclinical safety
Our results demonstrate that both PGRN and Atsttrin can pre-
vent and ameliorate inﬂammatory arthritis in preclinical animal
models without observable adverse effects [18]. Although this
may present a case for advancing both agents to clinically based
human study, we found several factors that may provide Atsttrin
with an advantage over PGRN in the potential treatment of inﬂam-
matory disease. For instance, PGRN is known to be an oncogenic
growth factor, and may contribute to tumorgenesis [2,86]. As de-
scribed above, not only did Atsttrin not possess oncogenic activity,
but it may even function as a tumor-suppressor (Tang and Liu,
unpublished data). Additionally, although PGRN exhibited a higher
binding afﬁnity to both TNFR1 and TNFR2 when compared with
TNFa, Atsttrin demonstrated 10-fold higher binding afﬁnity for
TNFR2, with a 18-fold lower afﬁnity for TNFR1 when compared
with TNFa [18]. We also observed that while PGRN could interact
with several other members of the TNFR subfamily (although with
lower afﬁnity than TNFR), Atsttrin selectively interacted with
TNFR1 and TNFR2, with a higher binding afﬁnity to TNFR2 [18].
This would suggest that the administration of Atsttrin would
potentially result in fewer adverse events than that of PGRN. In-
deed, Atsttrin did not exhibit any cytotoxic effects, even at exceed-
ingly high dosages in rhabdomyosarcoma A673/6 cells.
Furthermore, DBA1/J mice were injected daily with a high dose
of Atsttrin, and the heart, lung, stomach, spleen, pancreas, small
intestine, and colon were collected with no observed defects (Tang
C.-j. Liu / FEBS Letters 585 (2011) 3675–3680 3679and Liu, unpublished data). No overt toxicity or lethality related to
Atsttrin administration was observed throughout our study.
7. Conclusion and perspective
The understanding of the precise etiology, pathogenesis and
progression of arthritic diseases remains beyond our reach. Using
a functional genomic approach combined with biochemistry, cellu-
lar biology, and molecular biology techniques, PGRN growth factor
has been isolated and shown to physically associate with extracel-
lular matrix proteins (COMP [16], ECM1 [43], Perlecan [47]), prote-
lytic enzymes (elastase [8] and proteinase 3 [7], ADAMTS-7 [50],
ADAMTS-12 [15]), and TNF receptors (TNFR1 and TNFR2 [18]).
Thus, PGRN and its binding partners constitute interplay networks
and act in concert in mediating the pathogenesis of arthritis [17].
In addition, we have discovered and produced an engineered
PGRN-derived protein, Atsttrin, which effectively prevents the on-
set and progression of inﬂammatory arthritis in several preclinical
animal models [18]. With the consideration that TNFR signaling is
involved in a plethora of disease processes, manipulation of new
antagonists of the TNF/TNFR pathway may lead to innovative ther-
apeutics for various pathologies and conditions, such as rheuma-
toid arthritis.
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